Vol 53, No 1 (2022)
Short communication
Published online: 2022-02-25
Ruxolitinib for steroid-refractory acute graft versus host disease: case series and literature review
Acta Haematol Pol 2022;53(1):66-68.
Abstract
Not required
Keywords: acute graft versus host diseaseallogeneic hematopoietic stem cell transplantationruxolitinibimmunosuppression
References
- Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012; 18(8): 1150–1163.
- Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014; 49(2): 168–173.
- Przepiorka D, Luo L, Subramaniam S, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020; 25(2): e328–e334.
- Zeiser R, von Bubnoff N, Butler J, et al. REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020; 382(19): 1800–1810.
- Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6): 825–828.
- Elli EM, Baratè C, Mendicino F, et al. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol. 2019; 9: 1186.
- Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014; 123(24): 3832–3842.
- Jagasia M, Perales MA, Schroeder M, et al. Results from REACH1, a single-arm phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease. Blood. 2018; 132(Suppl 1): 601–601.
- Gomez VE, Garcia-Gutierrez V, Corral LL, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter study. Bone Marrow Transplant. 2020; 55(3): 641–648.
- Abedin S, McKenna E, Chhabra S, et al. Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(8): 1689–1694.
- Chang YJ, Zhao XY, Huang XJ. Strategies for enhancing and preserving anti-leukemia effects without aggravating gaft-versus-host disease. Front Immunol. 2018; 9: 3041.
- Choi J, Cooper ML, Alahmari B, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014; 9(10): e109799.
- Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10): 2062–2068.
- Mohty M, Holler E, Jagasia M, et al. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood. 2020; 136(17): 1903–1906.
- Liu Y, Fan Yi, Zhang W, et al. Efficiency and toxicity of ruxolitinib as the salvage treatment in steroid-refractoryc acute graft-versus-host disease after haplo-identical stem cell transplantation. Transplant Cell Ther. 2021; 27(4): 332.e1–332.e8.